Ferring Position on Presidential Executive Order on In Vitro Fertilization
Ferring is encouraged to see President Trump’s Executive Order aimed at finding ways to make in vitro fertilization (IVF) more accessible. With an estimated 1 in 6 people experiencing infertility, IVF is a proven scientific innovation that has helped millions of aspiring parents realize their dream of parenthood.
For more than 50 years, Ferring has been at the forefront in reproductive medicine, including developing innovative therapies, funding research in infertility, and working to expand access to care. Ferring is deeply committed to helping more people become parents, and we look forward to engaging with the Administration on this important initiative.
###
About Ferring Pharmaceuticals
Ferring Pharmaceuticals is a privately-owned, research-driven, specialty biopharmaceutical group committed to building families and helping people live better lives. In the United States, Ferring is a leader in reproductive medicine and in areas of gastroenterology and orthopaedics. We are at the forefront of innovation in microbiome-based therapeutics and uro-oncology intravesical gene therapy. Our company was founded in 1950 and is headquartered in Saint-Prex, Switzerland. Ferring employs more than 7,000 people worldwide and markets its medicines in over 100 countries. Ferring USA is based in Parsippany, New Jersey, and employs more than 900 employees.
For more information, please visit www.ferringusa.com, call 1-888-FERRING (1-888-337-7464), or connect with us on LinkedIn, and X (Twitter).
US Communications
Tel. (862) 286-5035
Email: US.Communications@Ferring.com